Pharmacogenomics and adverse drug reactions; prospective screening for risk identification

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 1, 2009, Pages 27-30

  Johnson, D E ^a,b   Smith, D A ^c   Park, B K ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Emiliem Inc   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMOXICILLIN PLUS CLAVULANIC ACID; ATOMOXETINE; AZATHIOPRINE; CAPECITABINE; CARBAMAZEPINE; CELECOXIB; DNA; FLUOROURACIL; FLUOXETINE; FOSPHENYTOIN SODIUM; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; ISONIAZID; NILOTINIB; PHARMACOLOGICAL BIOMARKER; PHENYTOIN; PROTEINASE INHIBITOR; RASBURICASE; RIFAMPICIN; STAVUDINE; VALPROATE SEMISODIUM; VALPROIC ACID; VARENICLINE; VORICONAZOLE; WARFARIN;

AUTOMUTILATION; BONE MARROW TOXICITY; DIARRHEA; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; EDITORIAL; FALLING; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEMOLYSIS; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; LACTIC ACIDOSIS; LIPOATROPHY; LIVER TOXICITY; MYOPATHY; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PHARMACOGENOMICS; PHARMACOKINETICS; PUBLIC HEALTH PROBLEM; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; SUICIDE; TRAFFIC ACCIDENT;

DRUG TOXICITY; HUMANS; PHARMACOGENETICS; RISK ASSESSMENT;

EID: 58449110289     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. J Am Med Assoc (1998) 279(15):1200-1205.
2. Passarelli MC, Jacob-Filho W, Figueras A: Adverse drug reactions in an elderly hospitalized population: Inappropriate prescription is a leading cause. Drugs Aging (2005) 22(9):767-777.
3. Laroche M-L, Charmes J-P, Nouaille Y, Picard N, Merle L: Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol (2006) 63(2):177-186.
4. Franceschi M, Scarcelli C, Niro V, Seripa D, Pazienza AM, Pepe G, Colusso AM, Pacilli L, Pilotto A: Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf (2008) 31(6):545-556.
5. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M: Incidence of adverse drug reactions in paediatric in/out-patients: A systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol (2001) 52(1):77-83.
6. Moore TJ, Cohen MR, Furberg CD: Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med (2007) 167(16):1752-1759.
7. Wilke R, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM: Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges. Nat Rev Drug Disc (2007) 6(11):904-916.
8. Nakamura Y: Pharmacogenomics and Drug Toxicity. N Engl J Med (2008) 359(8):856-858.
9. Ingelman-Sundberg M: Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med (2008) 358(6):637-639.
10. The SEARCH Collaborative group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R: SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med (2008) 359(8):789-799.
11. FDA ALERT (11/24/08): Information for Healthcare Professionals Phenytoin (marketed as Dilantin, Phenytek and generics) and Fosphenytoin Sodium (marketed as Cerebyx and generics). (http://www.fda.gov/cder/drug/ InfoSheets/HCP/phenytoin-fosphenytoinHCP.htm)
12. Bonnet E, Bernard J, Fauvel J, Massip P, Ruidavets J-B, Perret B: Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients. AIDS Res Human Retrovir (2008) 34(2):169-171.
13. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB: Alternative isoform regulation in human tissue transcriptomes. Nature (2008) 456(7221):470-476.